Carolin Lieber

Dr. Carolin Lieber

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Klaudia ChrzastekKlaudia Chrzastek
Klaudia Chrzastek
CLCarolin Lieber
Carolin Lieber
Richard PlemperRichard Plemper
Richard Plemper
Highly pathogenic avian influenza viruses (HPAIVs) of the H5 subtype pose a continuous threat to animal and public health due to their zoonotic potential, rapid evolution, and ability to spread across continents. Since the emergence of the A/goose/Guangdong/1/96 (GsGD) H5 lineage in 1996, several clades have caused devastating outbreaks in poultry and wild bird populations, occasionally resulting in human infections. Of the many clades that have evolved, only three—clades 2.2, 2.3.2.1, and most recently 2.3.4.4b—have demonstrated the ability to spread globally. The 2.3.4.4b clade has raised significant concern due to its continuous geographic expansion, establishment in new ecosystems, including Antarctica, and increasing reports of mammalian infections, including companion animals, marine mammals, and livestock. Recently, cow-to-cow and cow-to-human transmission marked a paradigm shift in the epidemiology of avian influenza and emphasized the need for continued surveillance. This review summarizes the historical emergence, global spread, and molecular evolution of H5 HPAIVs with a specific focus on the recent expansion of clade 2.3.4.4b and its capacity for mammalian spillover.

2 January 2026 in Science Immunology
Verified
Journal Article
Closed access
VNVu L. Ngo
Vu L. Ngo
CLCarolin Lieber
Carolin Lieber
HAHirohito Abo
Hirohito Abo
MKMichal Kuczma
Michal Kuczma
JZJun Zou
Jun Zou
AGAndrew Gewirtz
Andrew Gewirtz
Respiratory viral infection induces depletion and dysfunction of alveolar macrophages (AMs), resulting in high-susceptibility to life-threatening bacterial pneumonia. Colonization of the intestine by segmented filamentous bacteria (SFB) reprograms AM to resist depletion. Hence, we examined whether SFB protected mice against secondary bacterial infection by Streptococcus pneumoniae , Haemophilus influenzae , or Staphylococcus aureus after influenza A virus (IAV) infection. SFB protected mice against these infections based on pathogen loads and disease symptoms. AM depletion and transplant indicated that SFB-induced AM reprogramming was necessary and sufficient for such protection. Ex vivo analysis revealed that AMs from SFB-colonized mice not only resisted IAV-induced depletion but also were epigenetically reprogrammed to preferentially use oxidative phosphorylation and complement-dependent phagocytosis, which enabled efficient killing of bacteria. AM from SFB-colonized mice held their enhanced antibacterial phenotype even when transplanted into an inflamed interferon-rich post–IAV environment. Thus, gut microbiota composition influences susceptibility to bacterial pneumonia, especially after respiratory viral infection.

22 May 2026 in Science Advances
Verified
Journal Article
Open access
CLCarolin Lieber
Carolin Lieber
JWJosef D. Wolf
Josef D. Wolf
MGMugunthan Govindarajan
Mugunthan Govindarajan
JYJeong-Joong Yoon
Jeong-Joong Yoon
ZSZachary M. Sticher
Zachary M. Sticher
Richard PlemperRichard Plemper
Richard Plemper
Orthoparamyxoviruses, such as human parainfluenza virus type 3 (HPIV3) and measles virus (MeV), are a major health threat. We discovered an orally efficacious broad-spectrum inhibitor of orthoparamyxovirus polymerases. However, here, we found that tolerability in higher mammals was limited. We report the development of the clinical candidate analog GHP-88310 (EIDD-3608), which combines improved oral efficacy with favorable tolerability in nonrodents (ferrets and dogs). GHP-88310 was active against HPIV3, Sendai virus (SeV), MeV, and related canine distemper virus (CDV). In 7-day tolerability studies, daily doses of 2000 mg/kg were well tolerated. Pharmacokinetic analysis revealed altered plasma exposure of GHP-88310 compared to the original hit. In HPIV3-infected cotton rats, GHP-88310 lowered the respiratory tract viral load. Dosing of ferrets infected with CDV, causing lethal measles-like disease, resulted in complete survival, reduction of viremia and shed viral load, and alleviated lymphocytopenia. Once-daily GHP-88310 was efficacious in the CDV-ferret and HPIV3-cotton rat models. The compound was sterilizing against HPIV3 at physiological concentrations in human airway epithelium organoids.

24 July 2026 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
CLCarolin Lieber
Carolin Lieber
JWJosef D. Wolf
Josef D. Wolf
CRClaire E. Ruckel
Claire E. Ruckel
LHLauren A. Harrison
Lauren A. Harrison
Richard PlemperRichard Plemper
Richard Plemper
The 2025/2026 measles resurgence in North America highlighted that antivirals may be valuable in protecting child health because of mounting vaccination hesitancy. The drug candidate GHP-88310 is an orally efficacious broad-spectrum orthoparamyxovirus polymerase inhibitor, but its effect on viral transmission is unclear. Here we used canine distemper virus, which causes measles-like disease in ferrets, and established direct-contact and airborne canine distemper virus transmission models to examine pharmacological suppression of virus spread. Prophylactic GHP-88310 administration alleviated clinical signs of direct contacts and all sentinels survived. Pre- and post-exposure prophylactic GHP-88310 given twice daily to air contacts prevented transmission. Once-daily prophylactic administration mediated complete survival with all air contacts undergoing seroconversion. Therapeutic treatment of air contacts mitigated clinical signs, and animals survived, whereas all vehicle-treated air contacts succumbed. Therapeutic treatment of infected source animals shortened the contagious phase by 5 days. These results establish conceptual proof that GHP-88310 can suppress social contact transmission. Therapeutic treatment of sources promises epidemiological gain in addition to therapeutic benefit.